Abstract

The Dana-Farber Cancer Institute is an independent teaching affiliate of the Harvard Medical School and supports a federally-designated Comprehensive Cancer Center.
The aims of the Institute's Center can be summarized as follows: (a) to develop and maintain clinical and laboratory research programs of high quality related to the biology, cause and prevention, diagnosis and treatment of cancer. (b)to serve as the major cancer center in the Harvard-Longwood medical area and to play a leadership role for cancer research in New England providing expertise in cancer diagnosis, treatment and prevention. (c) to participate in the research training of medical students, house staff, fellows and graduate students and to provide post-doctoral research training. To maintain these activities, the present application requests renewal of the Institute's Cancer Core Support Grant. In addition, as a Comprehensive Cancer Center, the institute aims to translate its research findings to provide optimal care for cancer patients and to add to the total oncology resources of the local and regional medical communities in terms of staff, facilities and expertise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006516-35S2
Application #
2856167
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-12-01
Project End
2000-01-31
Budget Start
1998-03-27
Budget End
1999-01-31
Support Year
35
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574
Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641
Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12

Showing the most recent 10 out of 411 publications